A view on EGFR-targeted therapies from the oncogene-addiction perspective

Article

Abstract: Tumor cell growth and survival can often be impaired by inactivating a single oncogen - a phenomenon

Palabras claves:

CETUXIMAB, Combination therapy, eGFR, Erlotinib, nimotuzumab, Oncogene addiction, Targeted therapy

Autores:

de Leon J., Moreno E., Pérez R., Tania Crombet

Fuentes:

scopus